Keros Therapeutics (KROS) Other Working Capital Changes (2019 - 2025)
Keros Therapeutics' (KROS) quarterly Other Working Capital Changes came in at -$770000.0 in Q3 2025, up 67.69% on a QoQ basis from -$2.4 million in Q2 2025.
Keros Therapeutics (KROS) Other Working Capital Changes (2019 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 5 years of Other Working Capital Changes data on file, last reported at -$770000.0 in Q3 2025.
- Quarterly Other Working Capital Changes changed N/A year-over-year to -$770000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $155000.0 (changed N/A YoY) and the FY2021 annual result came in at -$62000.0, up 83.51% from the prior year.
- Other Working Capital Changes climbed to -$770000.0 in Q3 2025, from -$2.4 million in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $10.8 million in Q2 2024 to a low of -$11.3 million in Q3 2024.
- A 5-year average of $1.1 million and a median of -$287000.0 in 2022 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 2780.0% in 2022, down 2580.0% in 2022.
- Tracing KROS's Other Working Capital Changes over 3 years: stood at -$16000.0 in 2021, then surged by 2612.5% to $402000.0 in 2022, then sank by 291.54% to -$770000.0 in 2025.
- The last three Other Working Capital Changes figures came in at -$770000.0 (Q3 2025), -$2.4 million (Q2 2025), and $3.3 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - |
| 10 | Keros Therapeutics | 216.02 Mn | -41.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.82 Mn |
| Dec 31, 2025 | 1.82 Mn |
| Dec 31, 2025 | 1.82 Mn |
| Sep 30, 2025 | -1.82 Mn |
| Sep 30, 2025 | -1.82 Mn |
| Sep 30, 2025 | -1.82 Mn |
| Jun 30, 2025 | -463,000.00 |
| Jun 30, 2025 | -463,000.00 |
| Jun 30, 2025 | -463,000.00 |
| Mar 31, 2025 | -1.59 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Dec 31, 2024 | 10.68 Mn |
| Dec 31, 2024 | 10.68 Mn |
| Dec 31, 2024 | 10.68 Mn |
| Sep 30, 2024 | -11.31 Mn |
| Sep 30, 2024 | -11.31 Mn |
| Sep 30, 2024 | -11.31 Mn |
| Jun 30, 2024 | 10.84 Mn |
| Jun 30, 2024 | 10.84 Mn |